IDEAYA Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 124
- Market Cap
- $3.3B
- Website
- http://www.ideayabio.com
- Introduction
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 420
- Registration Number
- NCT05987332
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 82
- Registration Number
- NCT05907954
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
- Conditions
- Advanced or Metastatic Solid TumorsBreast CancerEndometrial CancerColorectal CancerHead and Neck CancersOvarian CancerProstate CancerNsclc
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 216
- Registration Number
- NCT05787587
- Locations
- 🇺🇸
HonorHealth Research Institute, Phoenix, Arizona, United States
🇺🇸The Angeles Clinic, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 180
- Registration Number
- NCT04794699
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Conditions
- Metastatic Uveal MelanomaColorectal CancerCutaneous MelanomaOther Solid Tumors
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 341
- Registration Number
- NCT03947385
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸San Francisco Oncology Associates, San Francisco, California, United States
🇺🇸Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States